Self-targeted liposomes for enhancing chemotherapeutic efficacy of pancreatic cancer by degrading the extracellular matrix and eradicating intra-tumoral bacteria
- PMID: 40522076
- DOI: 10.1039/d5bm00786k
Self-targeted liposomes for enhancing chemotherapeutic efficacy of pancreatic cancer by degrading the extracellular matrix and eradicating intra-tumoral bacteria
Abstract
Pancreatic cancer is one of the lethal malignancies resulting from the dense extracellular matrix (ECM) hindering the diffusion of cancer-chemotherapeutics and the intra-tumoral bacteria promoting tumor growth and inactivating cancer-chemotherapeutics, causing poor treatment prognoses. It is difficult to exert efficacy spatiotemporally by combined administration of chemotherapeutics, ECM degradation agents and antibiotics, and this may disturb the microflora in critically ill patients. To establish intra-tumor co-delivery of cancer-chemotherapeutics, ECM degradation agents and antibiotics, self-targeting DCPA (2-(4-((1,5-bis(octadecyloxy)-1,5-dioxopentan-2-yl)carbamoyl)pyridin-1-ium-1-yl)acetate) liposomes with complexed water as pH responsive functionality were self-assembled and PEGylated ciprofloxacin was used as a lipid-membrane component, together with bromelain and gemcitabine loaded in-core (B/G-C/DCPA-H2O). These triple-loaded liposomes were stealthily transported in the blood circulation to accumulate in the acidic environment of the tumor site. Upon tumor self-targeting, DCPA-H2O and PEGylated ciprofloxacin became protonated, disturbing the balance in the lipid membrane to cause liposome burst and simultaneous release of bromelain, PEGylated ciprofloxacin and gemcitabine. Treatment of mice with these self-targeting liposomes yielded significantly higher responses in Escherichia coli infected pancreatic cancer with respect to both infection and tumor volume than the administration of bromelain, gemcitabine and gemcitabine loaded C/DCPA-H2O liposomes alone.
Similar articles
-
Proton-mediated burst of dual-drug loaded liposomes for biofilm dispersal and bacterial killing.J Control Release. 2022 Dec;352:460-471. doi: 10.1016/j.jconrel.2022.10.049. Epub 2022 Nov 1. J Control Release. 2022. PMID: 36341930
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Multi-Focused Acoustic Radiation Force Impulse Modulation of Murine Hepatic Xenografts Enhances Nanoscale DOX@Lip Delivery and Therapeutic Effect.Int J Nanomedicine. 2025 Jun 12;20:7359-7373. doi: 10.2147/IJN.S522247. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40529535 Free PMC article.
-
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090. Health Technol Assess. 2006. PMID: 16545208
-
Chemotherapy and radiotherapy for advanced pancreatic cancer.Cochrane Database Syst Rev. 2024 Dec 5;12(12):CD011044. doi: 10.1002/14651858.CD011044.pub3. Cochrane Database Syst Rev. 2024. PMID: 39635901
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous